2018 Leibovich Model for Renal Cell Carcinoma (RCC)
ورودیهای بالینی بیمار
حداقل ۱۸ — حداکثر ۱۰۰ • واحد: years
حداقل ۰.۵ — حداکثر ۲۵ • واحد: cm
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Low Risk0–4
- Intermediate Risk5–9
- High Risk10–14
- Very High Risk15–20
The 2018 Leibovich Model for Renal Cell Carcinoma (RCC) calculator is designed for bedside predicting progression-free and cancer-specific survival in patients with renal cell carcinoma (RCC) using clinical, surgical, and pathologic factors in clinical practice. The resulting score directly guides clinician decision-making regarding adjusting systemic.
Clinical Guidelines & Evidence
Predicts progression-free and cancer-specific survival in patients with renal cell carcinoma (RCC) using clinical, surgical, and pathologic factors
Clinical Indication
The 2018 Leibovich Model for Renal Cell Carcinoma (RCC) is indicated for bedside clinical practice to support Predicts progression-free and cancer-specific survival in patients with renal cell carcinoma (RCC) using clinical, surgical, and pathologic factors. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients with solid tumors or hematologic malignancies undergoing staging, systemic therapy tolerability assessment, or prognostic stratification. Clinical application is indicated across Medical oncology clinics, chemotherapy infusion suites, inpatient oncology services, and palliative care.
Limitations & Contraindications
Prognostic indices provide statistical cohort survival estimates and must not replace individualized patient goals of care.
Clinical Pearls & Action Plan
Standardized functional performance status (ECOG or Karnofsky) is an independent determinant of chemotherapy tolerance and survival.
Scoring based on clinical, surgical, and pathologic factors with separate models for progression-free survival (PFS) and cancer-specific survival (CSS)
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| age | integer | Yes | Patient's age at surgery in years(years) |
| ecog_status | string | Yes | ECOG Performance Status |
| constitutional_symptoms | boolean | Yes | Presence of constitutional symptoms (fever, night sweats, weight loss) |
| adrenalectomy | boolean | Yes | Adrenalectomy performed during surgery |
| surgical_margins | string | Yes | Surgical margin status |
| tumor_grade | string | Yes | Tumor grade (Fuhrman/WHO-ISUP grading) |
| coagulative_necrosis | boolean | Yes | Presence of coagulative tumor necrosis |
| sarcomatoid_differentiation | boolean | Yes | Presence of sarcomatoid differentiation |
| tumor_size | float | Yes | Maximum tumor diameter in centimeters(cm) |
| perinephric_invasion | boolean | Yes | Invasion of perinephric fat or renal sinus fat |
| tumor_thrombus | string | Yes | Presence and level of tumor thrombus |
| extension_beyond_kidney | boolean | Yes | Extension beyond kidney capsule |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 0–4 | Low Risk | Excellent prognosis |
| 5–9 | Intermediate Risk | Good prognosis |
| 10–14 | High Risk | Poor prognosis |
| 15–20 | Very High Risk | Very poor prognosis |
Evidence-Based References (EBM)
- Thompson RH, Leibovich BC, Cheville JC, et al. Negative impact of sarcomatoid differentiation on the outcome of clear cell renal cell carcinoma. Am J Surg Pathol. 2018;42(4):474-481.
- Leibovich BC, Blute ML, Cheville JC, et al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer. 2003;97(7):1663-71.
- Thompson RH, Cheville JC, Lohse CM, et al. Reclassification of patients with pT3 and pT4 renal cell carcinoma improves prognostic accuracy. Cancer. 2005;104(1):53-60.